Table 6 Combined analysis of association between XPD-751, ERCC1-118, TS-3′UTR and GSTP1-105 polymorphisms and survival after 5-FU/oxaliplatin chemotherapy for disseminated colorectal cancer

From: A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer

Number of favourable polymorphismsa

Patients (N=103)b

Relative risk (95% CI)

Median survival (95% CI)

P-valuec

Lys/Lys, C/C, Val/Val, +6BP/+6BP

   

<0.001

 ⩾2

30

1

17.4 months (9.4, 26.5)

 

 1

48

2.14 (1.09, 4.22)

10.2 months (6.8, 15.3)

 

 0

25

3.75 (1.78, 7.89)

5.4 months (4.3, 6.0)

 

 Unknown

3

   
  1. 5-FU=5-fluorouracil; CI=confidence interval; GSTP=glutathione S-transferase; TS=thymidylate synthase; UTR=untranslated region.
  2. aFavourable genotypes of XPD-751 (Lys/Lys), ERCC1-118 (C/C), GSTP1-105 (Val/Val), and TS-3′UTR (+6BP/+6BP) polymorphisms.
  3. bCombined analysis was performed for only 103 out of 106 patients. Among the four patients with a missing data of the TS-3′UTR polymorphism, one patient was included since the patient had two favourable polymorphisms (ERCC1-118 and GSTP1-105).
  4. cBased on log-rank test.
Back to article page